• Agreement takes Gene Editing to Japanese Pharma

News & Views

Agreement takes Gene Editing to Japanese Pharma

A licensing agreement between Daiichi Sankyo and ERS Genomics provides the Japanese pharmaceutical company with access to foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, for use in its internal research and development to address areas of unmet medical need.

Eric Rhodes, CEO of ERS Genomics, said: “Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”

The Dublin-based company holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic.


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

Nano Tech 2025

Jan 29 2025 Tokyo, Japan

View all events